YM gets orphan drug status for JAK1/2 drug

The FDA has granted orphan drug status to YM BioSciences’ (TSX:YM; AMEX:YMI) JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, in which a patient’s bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory. The designation provides YM with seven years of U.S. marketing exclusivity, tax credits for clinical [...]

YM reshuffles the Cytopia deck

YM BioSciences (AMEX:YMI; TSX:YM) got more than it bargained for with its recent acquisition of Australia’s Cytopia. “When we were buying the company, our sole interest was in CYT997, Cytopia’s lead vascular disrupting agent (VDA),” CEO David Allan told biotuesdays.com in an exclusive interview.  VDAs, which can disrupt the blood flow that feed tumours, became [...]